Kenneth D Berlin

USPTO Granted Patents = 17 (Patent Applications = 1)

Average Co-Inventor Count = 4.6

ph-index = 6

Forward Citations = 191(Granted Patents)

Company Filing History:

9 out of 162

Oklahoma State University

patents

7 out of 38

Board of Regents for the Oklahoma Agricultural & Mechanical Colleges

patents

1 out of 832,912

Other

patents

Years Active: 1976-2024

Loading Chart...

17 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11993573 - Chromane-substituted, tetrahydroquinoline-substituted and thiochromane-substituted heteroarotinoids as anti-cancer agents (2024-05-28),

2. 10947198 - Chroman-substituted, tetrahydroquinoline-substituted and thiochroman-substituted heteroarotinoids as anti-cancer agents (2021-03-16),

3. 6586460 - Heteroarotinoids containing urea or thiourea linker (2003-07-01),

4. 5786481 - N-alkyl and N-acyl derivatives of 3,7-Diazabicyclo-�3.3.1!nonanes and (1998-07-28),

5. 5468858 - N-alkyl and n-acyl derivatives of 3,7-diazabicyclo-[3.3.1]nonanes and (1995-11-21),

6. 5268481 - 3-7-diheterabicyclo (3.3.1)nonanes and derivatives as antiarrhythmic (1993-12-07),

7. 5110933 - Salts of 3-azabicyclo[3.3.1]nonanes as antiarrhythmic agents, and (1992-05-05),

8. 5084572 - Salts of 3-azabicyclo [3.3.1]nonanes as antiarrhythmic agents, and (1992-01-28),

9. 5043445 - Bis-1,3-diazine heterocyclic derivatives as antiarrhythmic agents (1991-08-27),

10. 4980468 - Polyheterobicyclotridecane compounds (1990-12-25),

11. 4977276 - Heteroarotinoids as anticancer agents (1990-12-11),

12. 4910311 - 3-7-diheterabicyclo[3.3.1]nonanes as antiarrhythmic agents (1990-03-20),

13. 4833254 - Heteroarotinoids as anticancer agents (1989-05-23),

14. 4826984 - Heteroarotinoid compounds as anticancer agents (1989-05-02),

15. 4778892 - Certain 3-selena-7-aza-bicyclo[3.3.1]nonanes as antiarrhythmic agents (1988-10-18),

Title: Unveiling the Inventive Genius of Kenneth D. Berlin

Introduction:

Kenneth D. Berlin, a prolific inventor based in Stillwater, OK (US), has left an indelible mark on the field of cancer research and pharmaceuticals. With an impressive portfolio of 16 patents to his name, Berlin's groundbreaking work in developing anti-cancer agents has garnered widespread acclaim.

Latest Patents:

Among Berlin's latest patents is his groundbreaking work on Chroman-substituted, tetrahydroquinoline-substituted, and thiochroman-substituted heteroarotinoids as anti-cancer agents. These chemical compounds exhibit remarkable properties in inhibiting cancer cell growth, offering new hope in the fight against this insidious disease. Additionally, his innovative heteroarotinoids containing urea or thiourea linkers showcase his unwavering commitment to pioneering novel therapeutic solutions.

Career Highlights:

Kenneth D. Berlin's professional journey has been deeply intertwined with esteemed institutions such as Oklahoma State University and The Board of Regents for the Oklahoma Agricultural and Mechanical. His tenure at these institutions underscores his dedication to advancing scientific knowledge and translating research findings into tangible solutions. Berlin's contributions have not only enhanced the academic landscape but have also brought about tangible benefits for society at large.

Collaborations:

In his quest for scientific excellence, Kenneth D. Berlin has collaborated closely with notable peers such as Benjamin J. Scherlag and Mark D. Thompson. These collaborations have been instrumental in fostering a synergistic environment where ideas flourish, leading to the creation of innovative solutions that have the potential to transform lives.

Conclusion:

In conclusion, Kenneth D. Berlin stands as a beacon of innovation in the realm of cancer research, with his patents serving as a testament to his unwavering commitment to scientific advancement. His work continues to inspire future generations of inventors and researchers to push the boundaries of what is possible in the quest for novel therapies.

This text is generated by artificial intelligence and may not be accurate.

Please report any incorrect information to support@idiyas.com